119 related articles for article (PubMed ID: 30342000)
1. SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma.
Kaczorowski M; Biecek P; Donizy P; Pieniazek M; Matkowski R; Halon A
Transl Res; 2019 Feb; 204():72-81. PubMed ID: 30342000
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
Azimi F; Scolyer RA; Rumcheva P; Moncrieff M; Murali R; McCarthy SW; Saw RP; Thompson JF
J Clin Oncol; 2012 Jul; 30(21):2678-83. PubMed ID: 22711850
[TBL] [Abstract][Full Text] [Related]
3. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
6. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo.
Javelaud D; Delmas V; Möller M; Sextius P; André J; Menashi S; Larue L; Mauviel A
Oncogene; 2005 Nov; 24(51):7624-9. PubMed ID: 16007121
[TBL] [Abstract][Full Text] [Related]
7. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
Fairbairn NG; Orfaniotis G; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
[TBL] [Abstract][Full Text] [Related]
10. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
11. Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients.
Tas F; Erturk K
Cancer Invest; 2017 Sep; 35(8):501-505. PubMed ID: 28799813
[TBL] [Abstract][Full Text] [Related]
12. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
13. Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma.
Lee DY; Lau BJ; Huynh KT; Flaherty DC; Lee JH; Stern SL; O'Day SJ; Foshag LJ; Faries MB
J Am Coll Surg; 2016 Jul; 223(1):9-18. PubMed ID: 27236435
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
15. The intriguing effect of delay time to sentinel lymph node biopsy on survival: a propensity score matching study on a cohort of melanoma patients.
Tejera-Vaquerizo A; Descalzo-Gallego MA; Traves V; Requena C; Bolumar I; Pla A; Nagore E
Eur J Dermatol; 2017 Oct; 27(5):487-495. PubMed ID: 28944755
[TBL] [Abstract][Full Text] [Related]
16. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
[TBL] [Abstract][Full Text] [Related]
19. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
[TBL] [Abstract][Full Text] [Related]
20. Is sentinel lymph node biopsy of therapeutic relevance for melanoma?
Möhrle M; Schippert W; Rassner G; Garbe C; Breuninger H
Dermatology; 2004; 209(1):5-13. PubMed ID: 15237261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
